Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection

BMJ Case Rep. 2018 Mar 17:2018:bcr2017222582. doi: 10.1136/bcr-2017-222582.

Abstract

Thrombotic microangiopathy (TMA) comprises a process of sequential endothelial damage, microvascular thrombosis, consumptive thrombocytopenia and microangiopathic haemolytic anaemia that can affect several organs, including the kidney. A 36-year-old woman was presented with a petechial rash 3 weeks after an upper respiratory tract infection. Laboratory results showed normocytic normochromic anaemia, thrombocytopenia and evidence of TMA with decreased haptoglobin, elevated serum lactate dehydrogenase and a peripheral blood smear with numerous schistocytes. Treatment included daily plasmapheresis and prednisolone, with favourable clinical evolution. Antibodies anti-ADAMTS13 were positive, establishing the diagnosis of acquired thrombotic thrombocytopenic purpura. There was also serological evidence of a recent infection by Mycoplasma pneumoniae, and therefore the preceding respiratory tract infection by this agent was the most likely trigger for the disease. Due to the high mortality rate and poor outcomes, the prompt diagnostic and treatment are crucial in this rare disease. The identification of triggers related to this pathology can allow new therapeutic targets or preventive strategies.

Keywords: haematology (incl blood transfusion); immunology; renal medicine.

Publication types

  • Case Reports

MeSH terms

  • ADAMTS13 Protein / blood
  • ADAMTS13 Protein / metabolism
  • Acute Disease
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Autoantibodies / blood
  • Autoantibodies / metabolism
  • Diagnosis, Differential
  • Female
  • Humans
  • Plasma Exchange
  • Pneumonia, Mycoplasma / complications*
  • Prednisolone / administration & dosage
  • Purpura, Thrombotic Thrombocytopenic / complications*
  • Purpura, Thrombotic Thrombocytopenic / diagnosis
  • Purpura, Thrombotic Thrombocytopenic / therapy

Substances

  • Anti-Inflammatory Agents
  • Autoantibodies
  • Prednisolone
  • ADAMTS13 Protein

Supplementary concepts

  • Thrombotic thrombocytopenic purpura, acquired